Alejandro
Martín García Sancho
Profesor Asociado CC. Salud
Miguel Angel
Canales Albendea
Miguel Angel Canales Albendea-rekin lankidetzan egindako argitalpenak (5)
2019
-
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807
-
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966
2006
-
Treatment options in relapsed or refractory Hodgkin disease patients: The mini-BEAM regimen does exist too [1]
British Journal of Haematology
2001
-
Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease
Haematologica, Vol. 86, Núm. 5, pp. 494-498
-
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease
British Journal of Haematology, Vol. 113, Núm. 1, pp. 161-171